Hybrid closed-loop effectiveness in adults
What this study tests
Four-arm randomized trial in adults with T1D on multiple daily injections (MDI), comparing BetaBionics iLet, Insulet OP 5 (Omnipod 5), Tandem Control-IQ or continued MDI, all with CGM. Primary assessment is time in range at 39 weeks; no results are posted on the registry.
Editorial review: .
Registry checked: 2026-09-17. Registry’s own update: 2026-04-01.
Source dates appear in the references where available; this record has no dated citation metadata.
Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence
Evidence at a glance
- Who can enter the study?
- Ages 18–75 with T1D for at least 12 months and multiple daily injections (MDI) for at least 6 months, HbA1c at least 7% without a specified upper limit, and insulin needs at least 10 units/day. Current pump/AID use is excluded. Registered eligibility ↗Enrollment criteria describe who may enter. They do not establish who was analyzed or the denominator for a reported result.
- Reported benefit and results
- No results posted yet.Read the result sources and their limitations →
- Important harms
- Read the reported results, safety discussion and original sources. A separate harms summary is not available; this does not establish safety.
- Research access and approval
- Study regions: United States. A trial listing does not establish product approval or current recruitment at a particular site. Check the study’s current entry requirements.
- What remains uncertain?
- Read the full discussion and original sources for study limitations. Planned endpoints and completion dates are not results.
Research status alone does not establish approval, clinical benefit or local availability.
Primary endpoints
- Glucose time-in-range (TIR) of 70-180 mg/dL
The full picture
This record has no longer discussion. Use the study criteria, reported results and original sources on this page to assess what is known and what remains unresolved.
Sources
- [1]NCT06236607: Hybrid closed-loop effectiveness in adults · Trial registry